Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China
· Delayed Price · Currency is CNY 12.42
+0.18 (1.47%)
Mar 10, 2026, 3:04 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 84.13M CNY in the quarter ending September 30, 2025, a decrease of -8.68%. This brings the company's revenue in the last twelve months to 430.77M, down -5.24% year-over-year. In the year 2024, Hubei Biocause Heilen Pharmaceutical had annual revenue of 445.86M, down -32.75%.
Revenue (ttm)
430.77M
Revenue Growth
-5.24%
P/S Ratio
12.04
Revenue / Employee
436.44K
Employees
987
Market Cap
5.19B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fuan Pharmaceutical (Group) | 1.71B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Nanjing Hicin Pharmaceutical | 615.39M |
| Beijing Science Sun Pharmaceutical | 402.23M |
| Zhejiang Yatai Pharmaceutical | 326.64M |
| Ningbo Menovo Pharmaceutical | 1.54B |
| Hunan Fangsheng Pharmaceutical | 1.68B |
| Zhuhai Rundu Pharmaceutical | 1.19B |